Louis Lopez, MD
Cardiovascular Disease · Fort Wayne, INNPI 1922117571
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $26,830 of the $35,716 with a category attached, or 75.1%. 50 manufacturers reported payments, led by Boston Scientific at 38.0% of the total. Among cardiovascular disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 603 payments — averaging $59.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$14K
- Medtronic$6K
- Bard Peripheral Vascular, Inc.$3K
- Shockwave Medical, Inc$2K
- Reflow Medical Inc$2K
- Cardio Flow, Inc.$1K
- plus $9K from 44 others
Across 58 payments — averaging $1510.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$81K
- Philips North America LLC$4K
- Bard Peripheral Vascular, Inc.$2K
- Venturemed Group, Inc.$500
Across 7 payments — averaging $135.71 each. An ownership or investment interest held by the physician or an immediate family member.
- Verge Medical, Inc.$950
What the payments were for
- Consulting fees$4,67513%
- Travel & lodging$4,03611%
- Food & beverage$26,83075%
- Education$1760%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EKOSONIC$2,327
- GENERAL VASCULAR INTERVENTION$1,474
- IN.PACT Admiral$1,329
- HawkOne$920
- Rapiblyk$814
- NRG needle$761
- ELUVIA$665
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$618
- RotarexS 6 F x 135 cm$605
- LUTONIX$582
- Abre$518
- Lutonix Drug Coated Balloon$370
- Penumbra System$293
- JETSTREAM SC$260
- JETSTREAM$252
- ENROUTE Transcarotid Neuroprotection System$250
- RIVAL$210
- VIVA XT CRT-D$188
- CONCERTOTM$158
- VenaSeal$152
How this compares
$35,716 in reported general payments places this provider in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 491 | $575,763 |
| EntrestoSacubitril/Valsartan | 189 | $281,773 |
| XareltoRivaroxaban | 72 | $96,098 |
| CamzyosMavacamten | 12 | $86,534 |
| JardianceEmpagliflozin | 31 | $46,556 |
| FarxigaDapagliflozin Propanediol | 14 | $19,914 |
| BrilintaTicagrelor | 19 | $16,466 |
| Repatha SureclickEvolocumab | 25 | $16,041 |
| Varenicline Tartrate | 30 | $7,931 |
| SotalolSotalol Hcl | 317 | $7,424 |
| ClopidogrelClopidogrel Bisulfate | 664 | $6,605 |
| Repatha SyringeEvolocumab | 11 | $6,333 |
| Ranolazine ErRanolazine | 30 | $5,882 |
| Atorvastatin Calcium | 502 | $3,540 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 131 | $3,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $580 | $575,763491 claims |
| NovartisEntresto | $367 | $281,773189 claims |
| Johnson & JohnsonXarelto | $490 | $96,09872 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $123 | $86,53412 claims |
| Boehringer IngelheimJardiance | $143 | $46,55631 claims |
| AstraZenecaFarxiga, Brilinta | $292 | $36,38033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Fort Wayne
- Michael MirroFort Wayne$57K
- Issa KutkutFort Wayne$18K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
- Atul ChughIndianapolis$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.